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Trisomy 14 is a rare recurrent cytogenetic abnormality in myeloid neoplasms; however, its clinicopathologic features have not
been well described. We report the clinicopathologic, immunophenotypic, and molecular genetic features of 16 cases of myeloid
neoplasms with isolated trisomy 14. Our results show that cases with isolated trisomy 14 encompass a heterogenous group of
myeloid neoplasms including myelodysplastic syndrome (MDS, 44%), myelodysplastic/myeloproliferative neoplasms (31%), and
acute myeloid leukemia (25%). The patients are usually elder (median age 71 years), and there is a male predominance (82%).
Multilineage dysplasia is noted in all cases. Oncogenic mutations of genes involved in cell proliferation and/or survival rarely
occur. Compared with cases of MDS with diploid karyotype, patients of MDS with isolated trisomy 14 demonstrate a similar
overall survival and rate of leukemia transformation.
1.Introduction
The occurrence of isolated gain of a chromosome is reported
in 6-7% of human malignancies; the most common of which
in myeloid neoplasms are chromosomes 8, 9, 13, and 21
[1]. Trisomy 14 (+14) as the sole cytogenetic abnormality is
rather uncommon and has been reported in the setting of
myeloid neoplasms [2–9]. Among the myeloid neoplasms,
myelodysplastic syndrome (MDS) is the most common,
followed by myelodysplastic/myeloproliferative neoplasms
(MDS/MPN) and acute myeloid leukemia (AML) [2–9].
Chronic myelomonocytic leukemia (CMML) and atypical
chronic myeloid leukemia, BCR-ABL1 negative, are the two
most common entities in the MDS/MPN group. The clin-
icopathologic features of myeloid neoplasms with isolated
trisomy 14 has not been well described. The prognostic
signiﬁcance of isolated trisomy 14 also remains elusive.
In this study, we report the clinicopathologic, immu-
nophenotypic and molecular genetic features of 16 cases
of myeloid neoplasms associated with isolated trisomy 14,
the largest series to date. In addition, the overall survival
between MDS patients with isolated trisomy 14 and those
with a diploid karyotype is compared.
2.MaterialsandMethods
2.1. Case Selection and Clinical Data. The study was con-
ducted according to an institutional review board-approved
laboratory protocol. Cases with isolated trisomy 14 in
bone marrow were collected from the database of the
Clinical Cytogenetic Laboratory at our institution between
July 1, 1998 and January 31, 2009. For prognosis com-
parison, because diploid karyotype has been deﬁned as a
good risk prognostic indicator in MDS [10], a diagnosis-
matched group of 19 cases with MDS and a diploid
karyotype was also collected from the same study period.
Clinical data was obtained from review of the medical
records.2 Journal of Biomedicine and Biotechnology
2.2. Morphologic Examination. We reviewed bone marrow
core biopsy, clot, aspirate smears, and touch imprints in all
cases.Decalciﬁedcorebiopsyandaspirateclotwereroutinely
processed and stained with hematoxylin and eosin (H&E).
Bone marrow cellularity was assessed in the core biopsy
specimens. Diﬀerential 500-cell counts were performed on
eithertouchimprintsoraspiratesmearsstainedwithWright-
Giemsa. Particular attention was paid to the presence of
dysplasia in granulocytes, erythrocytes, and megakaryocytes.
The percentages of blasts were recorded. The diagnoses of
MDS, MDS/MPN, and AML were made based on the 2008
World Health Organization (WHO) classiﬁcation [10]. All
cases were independently reviewed by three hematopatholo-
gists.
2.3. Immunophenotypic Analysis. Immunophenotypic anal-
ysis by ﬂow cytometry was performed on bone marrow
aspirate specimens using an FACScan or FACSCalibur
instrument (Becton-Dickinson Biosciences, San Jose, CA),
as described previously [11]. The blast population was gated
usingrightanglesidescatterandCD45expression.Thepanel
ofmonoclonalantibodiesincludedreagentsspeciﬁcforCD2,
CD3, CD5, CD7, CD10, CD13, CD14, CD15, CD19, CD20,
CD33, CD34, CD38, CD41, CD56, CD64, CD117, HLA-DR,
TdT, and myeloperoxidase (Becton-Dickinson Biosciences).
2.4. Conventional Cytogenetic and Fluorescence In Situ
Hybridization Analyses. Conventional cytogenetic analysis
was performed on metaphase cells prepared from bone
marrow aspirate specimens cultured for 24–48 hours using
standard techniques as described previously [12]. Giemsa-
banded metaphases were analyzed, and the results were
reported using the International System for Human Cytoge-
netic Nomenclature, 2009.
Fluorescence in situ hybridization (FISH) analysis was
performed on 2 cases with a questionable +14 clone on
interphase nuclei using LSI IgH (mapped to 14q32) dual
color, break apart probe (Vysis/Abbott Laboratories, Des
Plaines, IL) to conﬁrm the presence of trisomy 14 clone. Two
hundredinterphaseswereanalyzedforeachsample.Thecut-
oﬀ for the IgH triplication is 4.1%. Results with three intact
IgH signals conﬁrm the presence of trisomy 14.
2.5. Molecular Analysis. Molecular studies for mutations
in KIT (exons 8 and 17), KRAS and NRAS (codons 12,
13 and 61), FLT3 (internal tandem duplication (ITD) and
codons 835/836), NPM1 (exon 12), and JAK2 (V617F) were
performed as described previously [13]. DNA was extracted
from peripheral blood or bone marrow aspirates using
Autopure LS automated DNA extraction system (Qiagen,
Valencia, CA) and was ampliﬁed by polymerase chain
reaction (PCR) using gene speciﬁc primers. PCR products
werethenanalyzedformutationsbySangersequencingusing
BigDye Terminator Cycle Sequencing reagents (Applied
Biosystems, Carlsbad, CA) (KIT), pyrosequencing using
PSQ96 HS System (Qiagen) (KRAS, NRAS, JAK2), and DNA
fragment size analysis using 3130 Genetic Analyzer (Applied
Biosystems) (FLT3 and NPM1).
2.6. Statistical Analysis. By using the Kaplan-Meier method,
we calculated the overall survival of patients with myeloid
neoplasms and isolated trisomy 14. We further compared
the overall survival for patients with MDS and isolated
trisomy 14 with that for patients with MDS and diploid
karyotype using double-sided Log-rank test. Chi-Square test
was utilized to compare rate of progression to AML between
patients with MDS and isolated trisomy 14 and patients
with MDS and diploid karyocype. Results were considered
statistically signiﬁcant when P value is <.05 on both sides.
GraphPad Prism 5 (GraphPad Software, La Jolla, CA) was
used for statistical analysis.
3. Results
3.1. Classiﬁcation of Cases with Isolated Trisomy 14. We
identiﬁed a total of 16 patients with isolated trisomy 14 from
July 1, 1998 to January 31, 2009, including 7 cases of MDS, 5
casesofMDS/MPN,and4casesofAML.Themedianagewas
71 years (range, 51–86 years) with a male to female ration
of 12:4. The clinical and morphologic features as well as
conventionalcytogeneticresultsaresummarizedinTables1–
3 and described separately.
3.2. Myelodysplastic Syndromes with Isolated Trisomy 14.
A diagnosis of MDS was made in 7 patients (Table 1).
The median age of patients in this subgroup was 73 years
(range, 63–79), and the male to female ratio was 6:1.
At presentation in our institution, all patients had anemia
(median hemoglobin, 10.0g/dL; range, 8.1–10.8g/dL; ref-
erence range, 14.0–16.0g/dL for men, 12.0–14.0g/dL for
women). Three patients had leukopenia (median white
blood cell count, 4.2109/L; range, 1.6–8.8109/L; reference
range,4.0–11.0109/L),and4patientshadthrombocytopenia
(median platelet count, 79109/L; range, 23–465109/L; refer-
ence range, 140–440109/L).
The bone marrow cellularity ranged from 15 to 95%
(median,65%).Trilineagedysplasiawaspresentinall7cases.
The blast count ranged from 1 to 18% (median, 8%). The
cases were classiﬁed as refractory anemia with excess blasts
(RAEB) type 2 (RAEB-2, n = 2), RAEB-1 (n = 2), refractory
anemia with ring sideroblasts (RARS, n = 2), and refractory
cytopenia with multilineage dysplasia (RCMD, n = 1),
based on the WHO classiﬁcation. Using the International
Prognostic Scoring System (IPSS) [10], the MDS cases were
considered as high (n = 2), intermediate-2 (n = 1), and
intermediate-1 (n = 4) risk groups.
3.3. Myelodysplastic/Myeloproliferative Neoplasms with Iso-
latedTrisomy14. FivepatientshadadiagnosisofMDS/MPN
(Table 2). The median age of patients in this subgroup
was 72 years (range, 51–86), and the male to female
ratio was 2:3. Anemia was present in 4 patients (median
hemoglobin,10.8g/dL;range,8.8–13.7g/dL;referencerange,
14.0–16.0g/dL for men, 12.0–14.0g/dL for women). Four
had leukocytosis (median white blood cell count, 14.8109/L;
range, 7.6–19.2109/L; reference range, 4.0–11.0109/L), andJournal of Biomedicine and Biotechnology 3
Table 1: Clinical, morphologic, and cytogenetic characteristics of patients with myelodysplastic syndrome and isolated trisomy 14.
Age
(Y) Sex WBC
(109/L)
Hb
(g/dL)
Platelet
(109/L)
WHO
classiﬁcation Karyotype Cellularity
(%)
Blast
(%)
Trilineage
dysplasia
IPSS
score
79 M 4.2 10.1 79 RAEB-1 47, XY, +14 [3]/46,XY [14]9 0 8 Y e s 1 . 0
79 M 1.6 9.2 75 RAEB-2 47, XY, +14 [8]/46,XY [12]∗ 15 18 Yes 2.5
75 F 4.5 11.2 38 RAEB-1 47, XX, +14 [3]/46,XX [14]∗ 65 13 Yes 2.0
70 M 3.4 8.1 23 RAEB-2 46, XX, i(14)(q10) [8]9 0 1 3 Y e s 2 . 5
73 M 3.9 10.0 351 RARS 46, X, -Y,+14 [3]/45, X, -Y [2]/
46, XY [15]∗ 35 4 Yes 1.0
63 M 8.8 10.8 465 RARS 46, XY, i(14)(q10) [5]/46, XY
[15]∗ 60 2 Yes 0.5
68 M 6.0 8.5 156 RCMD 46, XY, i(14)(q10) [16]9 5 1 Y e s 0 . 5
∗Diploid karyotype at time of initial diagnosis.
Y: years; M: male; F: female; WBC: white blood cell; Hb: hemoglobin; RAEB: refractory anemia with excess blasts; RARS: refractory anemia with ring
sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia; IPSS: international prognostic scoring system.
Table 2: Clinical, morphologic, and cytogenetic characteristics of patients with myelodysplastic/myeloproliferative neoplasms and isolated
trisomy 14.
Age
(Y) Sex WBC
(109/L)
Hb
(g/dL)
Platelet
(109/L)
WHO
classiﬁcation Karyotype Cellularity
(%) Blast (%) Trilineage
dysplasia IPSS score
68 M 14.8 13.7 626 CMML-1 47, XY, +14 [16]8 5 8 Y e s 1 . 0
72 M 18.6 8.8 198 CMML-1 47, XY, +14 [16]9 0 2 Y e s 0 . 5
86 F 11.3 10.8 171 CMML-1 47, XX, +14 [16]9 5 9 Y e s 1 . 0
51 F 7.6 12.3 160 CMML-2 46, XX, i(14)(q10) [16]3 51 7Y e s 2 . 0
77 F 19.2 9.7 291 MDS/MPN-U 47, XX, +14 [14]/46, XX
[3]∗ 100 6 Yes 1.0
∗Unknown karyotype at time of initial diagnosis.
Y: years; M: male; F: female; WBC: white blood cell; Hb: hemoglobin; CMML: chronic myelomonocytic leukemia; MDS/MPN-U: myelodysplas-
tic/myeloproliferative neoplasm, unclassiﬁable; IPSS: international prognostic scoring system.
one had thrombocytosis (median platelet count, 198109/L;
range, 160–626109/L; reference range, 140–440109/L).
The bone marrow cellularity ranged from 35 to 100%
(median,95%).Trilineagedysplasiawaspresentinall5cases.
The blast count ranged from 2 to 17% (median, 8%). The
cases were classiﬁed as chronic myelomonocytic leukemia
(CMML) type 1 (n = 3), CMML-2 (n = 1), and MDS/MPN,
unclassiﬁable (MDS/MPN-U, n = 1), based on the WHO
classiﬁcation. Using the International Prognostic Scoring
System (IPSS) [10], the MDS/MPN cases were considered
as intermediate-2 (n = 1) and intermediate-1 (n = 4) risk
groups.
3.4. Acute Myeloid Leukemia with Isolated Trisomy 14. Four
patients were diagnosed with AML (Table 3). The median
age of patients in this subgroup was 63 years (range, 57–
70), and the male to female ratio was 4:0. At presenta-
tion to our institution, all patients had anemia (median
hemoglobin, 9.9g/dL; range, 8.1–10.3g/dL; reference range,
14.0–16.0g/dL for men, 12.0–14.0g/dL for women). Two
had leucopenia, and one had leukocytosis (median white
blood cell count, 3.2109/L; range, 1.1–162109/L; refer-
ence range, 4.0–11.0109/L), and 3 had thrombocytopenia
(median platelet count, 61109/L; range, 56–305109/L; refer-
ence range, 140–440109/L).
The bone marrow cellularity ranged from 25 to 95%
(median,70%).Trilineagedysplasiawaspresentinall4cases.
The blast count ranged from 30 to 60% (median, 44%).
Three cases were classiﬁed as AML with maturation, and the
other case was classiﬁed as AML without maturation.
3.5. Immunophenotypic Features. Flow cytometry immu-
nophenotyping was performed in 12 cases with a blast
count greater than 5%. In all cases assessed, the blasts
demonstratedmyeloidimmunophenotypepositiveforCD13
(12/12), CD33 (12/12), CD38 (12/12), CD117 (12/12), HLA-
DR (12/12), CD34 (11/12), myeloperoxidase (10/12), TdT
(3/12), CD7 (2/12), CD64 (2/12), and CD14 (1/12), and
negative for the rest of the markers assessed.
3.6. Cytogenetic Results. Five cases had a clone with an
isochromosome 14q, and the remainder had a typical tri-
somy 14 clone (Tables 1–3). Chromosome 14 is an acrocen-
tric chromosome. An isochromosome for 14q, i(14)(q10),
is formed by rearrangement of two homologous long arms
of chromosome 14 that are mirror image of each other
[18]. The short arm of chromosome 14 contains repetitive
ribosomal DNA; the loss of which is generally considered
inconsequential [15]. Therefore, the presence of an acquired
i(14)(q10) in addition to a normal copy of chromosome 144 Journal of Biomedicine and Biotechnology
Table 3: Clinical, morphologic, and cytogenetic characteristics of patients with acute myeloid leukemia and isolated trisomy 14.
Age
(Y) Sex WBC
(109/L)
Hb
(g/dL)
Platelet
(109/L) WHO classiﬁcation Karyotype Cellularity
(%)
Blast
(%)
Trilineage
dysplasia
70 M 4.3 10.3 56 AML with maturation 47, XY, i(14)(q10) [2]/46, XY
[17]∗ 55 26 Yes
61 M 162 8.1 63 AML with maturation 47, XY, +14 [16]9 5 6 0 Y e s
57 M 1.1 9.7 59 AML without
maturation 47, XY, +14 [2]/46, XY [17]∗ 25 50 Yes
65 M 2.1 10.1 305 AML with maturation 47, XY, +14 [16]8 5 3 7 Y e s
∗Abnormal clone conﬁrmed by FISH.
Y: years; M: male; F: female; WBC: white blood cell; Hb: hemoglobin.
containsessentiallythesamegenomicmaterialastrisomy14,
and cases with i(14)(q10) are also included in this study.
Trisomy 14 was detected at initial diagnosis of all AML,
4 of 5 MDS/MPN, and 3 of 7 MDS cases. In the other 4
MDS cases, trisomy 14 occurred at 4, 5, 13, and 40 months
afterinitialdiagnosis,respectively.In1caseofMDS/MPN-U,
the initial karyotype was unknown, and the trisomy 14 was
identiﬁed when the patient presented to our institution 30
months after initial diagnosis. Of the 16 patients, 8 also had
a diploid clone. There was no evidence of clonal evolution
in any of the 16 cases, even during the course of disease
progression or leukemic transformation.
Fluorescence in situ hybridization (FISH) analysis was
performed using LSI IgH (mapped to 14q32) dual color,
break apart probe in 2 cases of AML that showed +14 in
two metaphases by conventional cytogenetics analysis, and
the FISH results conﬁrmed the presence of trisomy 14 clone
in both cases (Table 3).
3.7. Mutational Status of Selected Molecular Markers. Anal-
yses on Class I mutations in KIT, RAS, FLT3, NPM1, and
JAK2 genes that aﬀect cell proliferation and/or survival were
performed in a subset of the cases. As shown in Table 4,
FLT3-ITD was identiﬁed in 1 case of MDS and 1 case of
AML, whereas KRAS mutation was found in 1 MDS case and
NRAS mutation was present in 1 CMML-2 case. No other
mutations were detected in the rest of the patients. The MDS
patient who had FLT3-ITD mutation at initial presentation
subsequently developed AML, whereas the MDS patient
acquiredKRASmutationatthetimeofAMLtransformation.
The patient with CMML-2 and an NRAS mutation had
persistent disease at the last follow-up 28 months after initial
diagnosis.
3.8. Survival, Clinical Outcome and Acute Leukemic Transfor-
mation in Patients with Isolated Trisomy 14. All patients were
treated with chemotherapy. With a median follow-up of 21
months (range, 2–154 months), 11 patients died of disease,
and 5 patients had persistent disease. The overall survival
and rate of acute leukemic transformation for the three
groups of patients are illustrated in Table 5 and Figure 1.T h e
median survival was 28 months, 31.5 months, and 9 months
for patients with MDS, MDS/MPN, and AML, respectively.
Three of 7 (43%) patients with MDS and 1 of 5 (20%)
Table 4: Class I mutation status in patients with isolated trisomy
14.
Genes MDS MDS/MPN AML
FLT3 1/6 0/3 1/3
NPM1 0/5 0/3 0/3
C-KIT 0/4 0/3 0/3
RAS 1/7 1/4 0/3
JAK2 N/A 0/2 N/A
MDS:myelodysplasticsyndrome;MDS/MPN:myelodysplastic/myeloprolif-
erative neoplasms; AML: acute myeloid leukemia; N/A: not applicable.
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Figure 1: Overall survival of patients with myeloid neoplasms
associated with isolated trisomy 14.
patients with MDS/MPN developed AML with a median
interval of 18 months (range, 4–66 months).
3.9. Comparison between MDS Cases with Isolated Trisomy 14
andMDSCaseswithDiploidK aryotype. Wecomparedmajor
clinicopathologicandmoleculargeneticfeaturesbetweenthe
trisomy 14 MDS cases (n = 7) and diploid MDS cases
(n = 19)(Table6andFigure2).S imilart ocaseswithisolat ed
trisomy 14, the frequency of Class I mutations in KIT,Journal of Biomedicine and Biotechnology 5
Table 5: Median survival and disease progression in patients with isolated trisomy 14.
Features MDS (n = 7) MDS/MPN (n = 5) AML (n = 4)
Median survival (range) (month) 28 (10.5–75) 31.5 (31–32) 9 (2–12)
Leukemic transformation 43% 20% N/A
Median interval of disease progression (month) 7.75 29 N/A
MDS: myelodysplastic syndrome; MDS/MPN: myelodysplastic/myeloproliferative neoplasms; AML: acute myeloid leukemia; N/A: not applicable.
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Figure 2: Overall survival of patients with myelodysplastic syn-
drome and trisomy 14 versus diploid karyotype.
RAS, FLT3, and NPM1 was low in MDS cases with diploid
karyotype. Two diploid MDS cases had a gene mutation, one
in FLTT3 and the other in KRAS. No mutation was noted
in KIT or NPM1 gene. The median overall survival was 28
months and 14.5 months for cases with isolated trisomy 14
and those with diploid karyotype, respectively. Three of 7
patients with trisomy 14 and 4 of 19 patients with diploid
karyotype transformed to acute myeloid leukemia. However,
nostatisticallysigniﬁcantdiﬀerenceswereobservedinoverall
survival (P = .53, Log-rank test) and rate of leukemic
transformation between the two groups (P = .26, Chi-
Square test).
4. Discussion
Trisomy 14 as a sole chromosome abnormality is a rare
nonrandom cytogenetic abnormality in myeloid neoplasms
[19]. In review of the literature [2–9], a total of 75 cases
of myeloid neoplasms with isolated trisomy 14 have been
reported. However, the clinicopathologic features and prog-
nostic signiﬁcance of trisomy 14 are not well described. We
therefore report clinicopathologic, immunophenotypic, and
molecular genetic features in 16 cases of myeloid neoplasms
with isolated trisomy 14. In addition, we compare overall
survival and rate of leukemic transformation between MDS
cases with isolated trisomy 14 and MDS cases with a diploid
karyotype.
The clinical features of cases with isolated trisomy 14
in our study are similar to those that have been reported
previously in the literature. The median age of the reported
caseswas70.5years,whereasthemedianageinourstudywas
71 years, suggesting that patients with myeloid neoplasms
and isolated trisomy 14 are usually elderly. In addition,
we noted a male predominance with a male to female
ration of 12:4. Hematological features in those patients with
trisomy 14 described previously included monocytosis and
relatively preserved platelet count [5, 7, 8, 14, 17]. Absolute
monocytosis was present in 4 cases of CMML and 1 case
of RAEB-2 in our cohort. Platelet count was well preserved
in our series with a median of 158K/uL and a range of
23–626K/uL. This is in keeping with the blood cell count
reported previously.
Similar to the cases reported previously, our cases with
isolated trisomy 14 encompassed a spectrum of myeloid
malignancies including MDS, MDS/MPN, and AML. Addi-
tionally, in our study, MDS and MDS/MPN cases had an
initial IPSS score in the range of intermediate-1 to high risk
group, indicating that cases of MDS and MDS/MPN with
isolated trisomy 14 are heterogenous diseases. Morpholog-
ically, all cases showed signiﬁcant evidence of multilineage
dysplasia,andmostcasesshowedincreasedmyeloblasts,sup-
porting that these neoplastic processes aﬀect a multipotent
myeloid precursor.
Trisomy 14 was identiﬁed at initial diagnosis in most of
our cases, suggesting that this abnormality may represent
an early event in leukemogenesis. Emerging new clone with
del(20q) was previously reported in one MDS patient with
isolated +14 during disease progression [5]. Toze et al. also
showed an acquired trisomy 21 in an AML patient with
isolated+14duringdiseaserelapse[8].However,noevidence
of clonal evolution was observed in any of our patients
during disease progression or leukemic transformation,
which may be related to diﬀerent patient population and
diﬀerent treatment strategy. Furthermore, 50% of patients in
our study presented with a normal diploid cell line. This is in
accordance with previously reported cases [7, 8].
Theacquisitionofadditionalgeneticmutationsmaycon-
tribute to disease progression or leukemic transformation.
Activating mutations in tyrosine kinases, FLT3, KIT, and
JAK2,aswellasthoseinRASandNPM1,conferproliferation
and/or survival advantage to hematopoietic progenitors in
corporation with loss-of-function of hematopoietic tran-
scription factors [19]. Shih et al. [20] have shown that
acquisition of FLT3 or N-RAS mutations is frequently
associated with progression of MDS to AML. In our study,
Class I mutation was present in only four patients includ-
ing two MDS patients who eventually evolved into AML.6 Journal of Biomedicine and Biotechnology
Table 6: Clinical data for patients with myelodysplastic syndrome and isolated trisomy 14 or diploid karyotype.
Group Sex Age (year) OS (month)
M F Median Range Median Range Leukemictransformation
Diploid (n = 19) 12 7 66 38–84 14.5 0.6–129.5 4
+14 (n = 7) 6 1 73 63–79 28.0 8.9–110.0 3
M :m a l e ;F :f e m a l e ;Y :y e a r s ;O S :o v e r a l ls u r v i v a l .
The other one patient acquired Class I mutation during
disease progression. These ﬁndings suggest that trisomy 14
by itself may play an essential role in the initiation of these
neoplastic processes. It has been suggested that dosage eﬀect
of extra copy of genes is potentially associated with cell
proliferation [16].FOSand AKT1aretheoncogenesmapped
to 14(q21-q31) and 14(q32), respectively [8]. Increased FOS
expression has been identiﬁed in AML, especially recurrent
AML and familial MDS [21, 22]. Constitutively activated
AKT1 in mice can induce MPN, T-cell lymphoma, or AML
[23]. Furthermore, Jagged-2 (JAG2) (mapped to 14q32),
a Notch ligand, has been found to be overexpressed in
leukemic stem cells (LSCs) and inhibition of Jagged-2 can
leadtosuppressionofLSCgrowthincolonyformationassays
[24].
No prior studies regarding the prognostic signiﬁcance
of trisomy 14 in myeloid malignancy have been reported.
By comparing cases of MDS with isolated trisomy 14 and
those with a diploid karyotype, our study demonstrated
that MDS patients with isolated trisomy 14 had a similar
overall survival and rate of leukemic transformation to those
with a diploid karyotype. It is wellrecognized that cases
of MDS with diploid karyotype represent a heterogenous
group of diseases. Similarly, cases with isolated trisomy 14
are heterogenous and may encompass a spectrum of diseases
with diﬀerent molecular abnormalities.
In summary, we demonstrate that isolated trisomy 14 is
associatedwithavarietyofmyeloidneoplasmswithdysplasia
and often occurs in older patients. Class I mutations are
uncommon. Patients with MDS and isolated +14 have
similar overall survival and rate of leukemic transformation
as compared with MDS patients with diploid karyotype.
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